UNSPSC 51294411: Trazitiline

This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H24N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7I6MS3VHQE, chemically known as 1-(9,10-ethanoanthracen-9(10h)-yl)-4-methylpiperazine but generally known as trazitiline, which bears US NIH Compound Identifier 3084449. European Medicines Agency schedules Trazitiline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11222MIG.

UNSPSC 51294411 Trazitiline is a Commodity code that spans pharmaceutical products and drug-related medical supplies procured by state and local health agencies, though recent opportunities show the code being applied to naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription programs. State and local buyers under this code include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances serving participating government jurisdictions. Scope of work encompasses the supply of naloxone and drug deactivation systems for community health initiatives, generic pharmaceutical and OTC product distribution through authorized wholesalers with strict manufacturing and compliance certifications (cGMP, DSCSA, FDA requirements), and pharmacy benefit program modernization through direct contracting between state agencies and manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. Vendors typically must maintain substantial insurance coverage, comply with federal manufacturing standards, utilize electronic data interchange systems, and meet drug supply chain security requirements.

Geographic activity centers on Florida, Texas, and Minnesota, with multistate reach through cooperative purchasing mechanisms. Representative recent opportunities include Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) soliciting 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription contracting; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic pharmaceuticals and OTC products distributed across participating state and local facilities including Oregon, with contract effectiveness July 1, 2026 and evaluation weighted 75 percent on price competitiveness. The MMCAP procurement requires vendors to maintain relationships with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson) and accept a 3 percent administrative fee.